Basecamp Wealth Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
Basecamp Wealth Advisors's NVO Position: Q3 2026 in Review
Basecamp Wealth Advisors reduced its Novo Nordisk (NVO) stake by 2.1% in Q3 2026, selling an estimated $10.6K and leaving 10,728 shares worth $407K. The position accounts for 0.09% of the portfolio, ranked #111.
Basecamp Wealth Advisors first reported a position in NVO in Q4 2025 and has held it in 4 quarters since. The position peaked at $592K in Q4 2025. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Basecamp Wealth Advisors held 10,728 shares of Novo Nordisk worth $407K as of Q3 2026.
- Basecamp Wealth Advisors sold 230 Novo Nordisk shares in Q3 2026, an estimated $10.6K.
- Novo Nordisk made up 0.09% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #111 holding.
- Basecamp Wealth Advisors first reported a position in Novo Nordisk in Q4 2025 and has held it in 4 quarters since.
- Basecamp Wealth Advisors's Novo Nordisk position peaked at $592K in Q4 2025.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.